Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

Authors


  • The process of consensus update was sponsored by the Prosperous Foundation, Taipei, Taiwan, who received unrestricted grants from GSK, Roche, BMS and Sciclone.

  • Other members of the working party, consensus update on chronic hepatitis B. A. Chutaputti (Thailand), D. S. Chen (Taiwan), R. N. Chien (Taiwan), G. Cooksley (Australia), K. H. Han (Korea), T. Ichida (Japan), M. Y. Lai (Taiwan), L. Lesmana (Indonesia), T. Piratvisuth (Thailand), S. K. Sarin (India), J. Sollano (Philippines), D. J. Suh (Korea), G. B. Yao (China), C. T. Yeh (Taiwan), O. Yokosuka (Japan).

Prof. Yun-Fan Liaw, Liver Research Unit, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan.
Tel: 886 3 3281200 ext. 8120
Fax: 886 3 3282824
e-mail: liveryfl@so-net.net.tw

Abstract:

Background/Aims: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update.

Methods: New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL.

Results: Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested.

Conclusion: The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment.

Ancillary